SEARCH

SEARCH BY CITATION

References

  • 1
    Belle SH, Beringer KC, Detre KM. An update on liver transplantation in the United States: recipient characteristics and outcome. Clin Transpl 1995; 1933.
  • 2
    O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, Portmann B, et al. Hepatitis B virus reinfection after orthotopic liver transplantation: serological and clinical implications. J Hepatol 1992; 14:104111. MEDLINE
  • 3
    Todo S, Demetris AJ, Van Thiel D, Taperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus–related liver disease. Hepatology 1991; 13:619626. MEDLINE
  • 4
    Samuel D, Müller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with hepatitis B surface antigen. N Engl J Med 1993; 329:18421847. MEDLINE
  • 5
    Müller R, Gubernatis G, Farle M, Niehoff G, Klein H, Wittekind C, Tusch G, et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991; 13:9096. MEDLINE
  • 6
    Trautwein C, Schrem H, Tillmann HL, Kubicka S, Walker D, Böker KHW, Maschek HJ, et al. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. Hepatology 1996; 24:482488. MEDLINE
  • 7
    Tsiquaye KN, Slomka MJ, Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissue of ducklings infected in ovo. J Med Virol 1994; 42:306310. MEDLINE
  • 8
    Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88:84958499. MEDLINE
  • 9
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trail of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:26572661.
  • 10
    Böker KH, Ringe B, Krüger M, Pichlmayr R, Manns MP. Prostaglandin E plus famciclovir—a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994; 57:17061708. MEDLINE
  • 11
    Lin E, Luscombe C, Wang Y, Shaw S, Locarnini S. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1996; 40:413418. MEDLINE
  • 12
    Offensperger WB, Offensperger S, Keppler-Hafkemeyer A, Hafkemeyer P, Blum HE. Antiviral activities of penciclovir and famciclovir on duck hepatitis B virus in vitro and in vivo. Antiviral Ther 1996; 1:141146.
  • 13
    Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistance to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993; 90:56535656. MEDLINE
  • 14
    Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymease during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711713. MEDLINE
  • 15
    Bartholomow MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:2022. MEDLINE
  • 16
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA–dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714717. MEDLINE
  • 17
    Tipples GA, Ma MM, Fischer KP, Gutfreund KS, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV-RNA–dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24(Supp 1):283A.
  • 18
    Hankoop P, Niesters HGM, de Man RAM, Osterhaus ADME, Schalm S. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997; 26:13931395. MEDLINE
  • 19
    De Man RA, Bartholomeusz A, Locarnini S, Niesters HGM, Zondervan PE. The occurrence of sequential viral mutations in a liver transplant recipient re-infected with hepatitis B: primary famciclovir resistance followed by a lethal hepatitis during acquired lamivudine resistance. J Hepatol 26(Supp 1):77.
  • 20
    Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26:11481153. MEDLINE
  • 21
    Aye TT, Bartholomeusz AI, Shaw T, Breschkin AM, Gronen L, Bowden DS, McMillan J, et al. Hepatitis B virus polymerase mutations during famciclovir therapy in patients following liver transplantation. Hepatology 1996; 24(Suppl):285A.
  • 22
    Naoumov NV, Chokshi S, Smith H, Williams R. Emergence and Characterisation of lamivudine resistant hepatitis B virus variant. Hepatology 1996; 24:282A.
  • 23
    Neuhaus P, Manns M, Atkinson G. Safety and efficacy of famciclovir for the treatment of recurrent hepatitis B in liver transplant recipients. on behalf of the FCV liver transplant group Hepatology 1997; 26:A260.
  • 24
    Tillmann H, Trautwein C, Walker D, Michitaka K, Kubicka S, Böker K, Manns M. Clinical relevance of mutations in the precore genome of the hepatitis B virus. Gut 1995; 57:15881593.
  • 25
    Michitaka K, Durazzo M, Tillmann HL, Walker D, Philipp T, Manns MP. Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology 1994; 106:16031610. MEDLINE
  • 26
    Bartholomeusz A, Locarnini S. Mutations in hepatitis B virus polymerase gene associated with famciclovir and lamivudine. International Antiviral News 1997; 5:123124.
  • 27
    Galibert F, Mandart E, Fitoussi F, Tiollais P, Charay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in Escherichia coli. Nature 1979; 281:646650. MEDLINE
  • 28
    Valenzuel P, Quiroga M, Zaldivar J, Gray P, Rutter W. The nucleotide sequence of the hepatitis B genome and the identification of the major viral genes. In: FieldsB, JaenischR, FoxC, eds. Animal Virus Genetics. New York: Academic Press, 1980; 5770.
  • 29
    Carman WF, Trautwein C, Van Deursen FJ, Colman K, Dornan E, McIntyre G, Waters J, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24:489493. MEDLINE
  • 30
    Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997; 4(Suppl 1):1120. MEDLINE
  • 31
    McMahon G, Ehrlich PH, Moustafa ZA, McCarthy LA, Dottavio D, Tolpin MD, Nadler PI, et al. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody–treated liver transplant patients. Hepatology 1992; 15:757766. MEDLINE
  • 32
    Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Büschenfelde KH, Neuhaus P, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27:254263. MEDLINE
  • 33
    Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27:213222. MEDLINE
  • 34
    Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ, Williams R. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including an unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13:150157. MEDLINE
  • 35
    Bock CT, Tillmann HL, Maschek H, Manns MP, Trautwein C. A PreS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology 1997; 113:19761982. MEDLINE
  • 36
    Krüger M, Tillmann HL, Trautwein C, Bode U, Oldhafer K, Maschek H, Böker KHW, et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation. Liver Transplant Surg 1996; 2:253262.
  • 37
    Haller GW, Bechstein WO, Neuhaus R, Raakow R, Berg T, Hopf U, Neuhaus P. Famciclovir therapy for recurrent hepatitis B virus infection after liver transplantation. Transpl Int 1996; 9(Suppl 1):S210S212. MEDLINE
  • 38
    Zoulim F, Pichoud C, Wang Z, Aguesse-Germon S, Trépo C. Hepatitis B virus genome variability during famciclovir therapy. Hepatology 1997; 26:A428.
  • 39
    Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T, Wahlstrom E, Faruki H. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Hepatogastroenterology 1997; 44:808812. MEDLINE
  • 40
    Earnshaw DL, Bacon TH, Darlision SJ, Edmonds K, Perkins RM, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992; 36:27472757. MEDLINE
  • 41
    Luscombe CA, Locarnini SA. The mechanism of action of antiviral agents in chronic hepatitis B. Viral Hepat Rev 1996; 2:135.
  • 42
    Lai CL, Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, et al. 12 months of lamivudine (100mg od) therapy improves liver histology: results of a placebo controlled multicentre study in Asia. J Hepatol 1997; 26(Suppl 1):97.
  • 43
    Perrillo R, Rakela J, Martin P, Wright T, Levy G, Schiff E, Dienstag J, et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation. (OLT). Hepatology 1997; 27:260A.
  • 44
    Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, et al. Identification and biological characterization of mutants in HBV resistant to lamivudine. Hepatology 1998; 27:16701677. MEDLINE
  • 45
    Fischer KP, Tyrrell DL. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(—)-beta-l-2′,3′-dideoxy-3′thiacytidine] in vitro. Antimicrob Agents Chemother 1996; 40:19571960. MEDLINE
  • 46
    Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replicative defective. Hepatology 1998; 27:628633. MEDLINE
  • 47
    Fu L, Cheng YC. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in l(-SddC (3TC) resistance. Biochem Pharmacol 1998; 55:15671572. MEDLINE
  • 48
    Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26:216225. MEDLINE
  • 49
    Korba BE. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res 1996; 29:4951. MEDLINE
  • 50
    Mayers D. Rational approaches to resistance: nucleoside analogues. AIDS 1996; 10(Suppl 1):S9S13. MEDLINE
  • 51
    Moyle G. The role of combinations of HIV protease inhibitors in the management of persons with HIV infection. Exp Opin Invest Drugs 1998; 7:413426.
  • 52
    Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, Mcahon D, Jonas L, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection. JAMA 1998; 280:3541. MEDLINE
  • 53
    Chen YCJ, Delbrook K, Dealwis C, Mimms L, Mushahwar IK, Mandecki W. Discontinuos epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library. Proc Natl Acad Sci U S A 1996; 93:19972001. MEDLINE